

## Dr. Kyrre Thalberg new Senior Advisor in formulation development

**Iconovo AB (publ) has appointed dr. Kyrre Thalberg to be Senior Advisor in formulation development.**

Dr. Thalberg is an internationally renowned expert in development of dry powder formulations for inhalation. Over close to 30 years, he held many leading roles in formulation development at AstraZeneca. He has more than 50 academic publications, several patents and has supervised 5 Ph.D. students. He will take an active role in the development of formulations for Iconovo's new inhalation device ICOPre®. It will mainly be a generic version of Relvar© Ellipta©.

"We are very pleased to be able to attract such international authority on formulation development. This will further strengthen the high scientific level of our work and help us to accelerate the development of our generic Relvar ICOPre", says Johan Wäborg, CEO of Iconovo.

### About ICOPre®

ICOPre® is a pre-metered multi-dose inhaler for simple once-daily treatment. It works well with all types of inhalation powders. It has an easy three-step operation; open-inhale-close, like the well-known Ellipta® inhaler from GSK. With 30 aluminum-sealed doses, it provides one month of treatment. Each dose comes from two different cavities that are inhaled simultaneously, making ICOPre suitable for mono, duo and triple products. ICOPre has a precise dose-counter that shows the number of doses remaining. ICOPre is being developed based on a unique principle that will be protected by a number of patents.

<https://iconovo.se/products/icopre/>

### Contacts

---

#### Johan Wäborg, CEO

+46 707 78 51 71

[johan.waborg@iconovo.se](mailto:johan.waborg@iconovo.se)

### About Iconovo

---

Iconovo was founded in 2013 by people with long experience in inhalation development. The company develops inhalers and associated drug preparations that are used to treat asthma and COPD. However, Iconovo also has the competence to develop products for new types of inhaled drugs such as vaccines.

By working with Iconovo, pharmaceutical companies and generic companies can access a complete pharmaceutical product, thereby eliminating the complex and costly early stages of the development phase. Iconovo licenses its patented products to customers and offers a faster way to the inhalation market with lower risk and at a lower cost.

More information about the company can be found at [www.iconovo.se](http://www.iconovo.se).

Iconovo is based in Lund and its share (ticker ICO) is listed on Nasdaq First North Growth Market, Stockholm since April 6, 2018. The Company's Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm, phone +46 8 463 80 00, email: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se).

**Attachments**

---

[Dr. Kyrre Thalberg new Senior Advisor in formulation development](#)